{
    "data": [
        {
            "id": "4563640",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-09T18:42:36-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1446105962/image_1446105962.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina: Strong EPS Growth Expected, But Shares Richly Valued In A Risky Space",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425062",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563640-illumina-strong-growth-expected-but-shares-richly-valued"
            }
        },
        {
            "id": "4544107",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-01T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Investors Look For Edges Amid Inflation, Rates, Earnings Challenges",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544107-stocks-to-watch-investors-look-for-edges-amid-inflation-rates-earnings-challenges"
            }
        },
        {
            "id": "4543877",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-29T14:37:37-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413176878/image_1413176878.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina Engages Obama To Push Its Customers' Reimbursement Agenda",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "411695",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4543877-illumina-engages-obama-to-push-its-customers-reimbursement-agenda"
            }
        },
        {
            "id": "4537790",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-29T23:07:08-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/154959727/image_154959727.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina Needs Grail, But May Lose It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "406586",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4537790-illumina-stock-needs-grail-but-may-lose-it"
            }
        },
        {
            "id": "4530239",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-05T11:34:54-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363842522/image_1363842522.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Still Avoiding Illumina Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104099",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386248",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4530239-illumina-stock-valuation-avoid"
            }
        },
        {
            "id": "4524109",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-19T03:42:00-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343072621/image_1343072621.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Ensemble Capital Management - Illumina: Never Been So Cheap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105080",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524109-illumina-never-been-so-cheap"
            }
        },
        {
            "id": "4522869",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-12T08:14:25-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209892070/image_1209892070.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Potential Is There, But Illumina Has A Long Way To Go",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106651",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381868",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4522869-the-potential-is-there-but-illumina-has-a-long-way-to-go"
            }
        },
        {
            "id": "4519281",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-20T05:57:51-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344985871/image_1344985871.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina: Remains Investible Despite The GRAIL Issue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105503",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379043",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4519281-illumina-investible-despite-grail-issue"
            }
        },
        {
            "id": "4500553",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-09T02:29:40-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina: A Good Long-Term BioTech Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106304",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368156",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500553-illumina-stock-good-long-term-biotech-investment"
            }
        },
        {
            "id": "4500381",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-08T02:09:05-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1254979930/image_1254979930.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemistry X, Infinity, GRAIL: The New Illumina Is A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368492",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500381-chemistry-x-infinity-grail-illumina-buy"
            }
        },
        {
            "id": "4483050",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-31T18:38:41-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343072621/image_1343072621.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Illumina Stock: Exceptional Growth Marred By Contentious Acquisition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358736",
                            "type": "sentiment"
                        },
                        {
                            "id": "358737",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4483050-illumina-stock-exceptional-growth-marred-by-contentious-acquisition"
            }
        },
        {
            "id": "4482039",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-27T09:58:41-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307389080/image_1307389080.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Comparing Illumina And Pacific Biosciences In Light Of The New Market Regime",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105503",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358784",
                            "type": "sentiment"
                        },
                        {
                            "id": "358785",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2130",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4482039-comparing-illumina-and-pacific-biosciences-in-light-of-new-market-regime"
            }
        }
    ]
}